Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement...
Clinical Trial
Recent clinical data confirms significantly improved predictive power of Evaxion’s AI-Immunology™ platform
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates...
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical...
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients...
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical...
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting...
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization
VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today...
Spectral Medical Provides September Tigris Trial Update
• 132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),...
Closes Units for Debt Settlement
TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)...
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell...
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing...
DATAcc by DiMe Awarded FDA Grant to Boost Use of Sensor-Based Digital Health Technologies in Clinical Trials
DATAcc is creating an open-source industry guide to address market challenges by bringing clarity on how and why to include...
Positive Data from the First Part of IRLAB’s Phase I Study with the Drug Candidate IRL757
GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics...
Power Wins DPHARM Idol Disrupt, Building the Best Place for People to Connect with Medical Research Online
The First Digital Network for Research Flips the Script on Patient Recruitment PHILADELPHIA, Oct. 2, 2024 /PRNewswire/ -- Power, a...
Cancer centers launch Cancer AI Alliance to unlock discoveries, transform care using cancer data and applied AI
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with...
Life Science Analytics Market to Hit USD 61.94 Billion by 2029 with 11.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Oct. 2, 2024 /PRNewswire/ -- The global life science analytics market is projected to grow from USD 35.69...
Rice’s Biotech Launch Pad to lead commercialization of bioelectrical implant treatment for obesity, type 2 diabetes
$34.9M ARPA-H project aims to disrupt therapies' market and radically improve treatment options HOUSTON, Oct. 2, 2024 /PRNewswire/ -- Rice...